Modafinil augmentation therapy in unipolar and bipolar depression: A systematic review and meta-analysis of randomized controlled trials

Journal of Clinical Psychiatry

Volumn 74, Issue 11, 2013, Pages 1101-1107

  Goss, Alexander J ^a   Kaser, Muzaffer ^c,d   Costafreda, Sergi G ^b   Sahakian, Barbara J ^d   Fu, Cynthia H Y ^e  

^a Leeds School of Medicine   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c BAHCESEHIR UNIVERSITY   (Turkey)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF EAST LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARMODAFINIL; MODAFINIL; PLACEBO;

AUTONOMIC NEUROPATHY; BIPOLAR DEPRESSION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DSM-IV; FATIGUE; HEADACHE; HUMAN; ICD-10; INSOMNIA; MAJOR DEPRESSION; META ANALYSIS; MOOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SOMNOLENCE; SUICIDAL IDEATION; SYSTEMATIC REVIEW;

EID: 84889248859     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13r08560     Document Type: Review

References (40)

1. World Health Organization. Depression: a global public health concern. http://www.who.int/mental-health/management/depression/who-paper-depression- wfmh-2012.pdf. Accessed May 11, 2012.
2. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64(2):161-174. doi:10.408/JCP.v64n0209 PubMed
3. Maurice-Tison S, Verdoux H, Gay B, et al. How to improve recognition and diagnosis of depressive syndromes using international diagnostic criteria. Br J Gen Pract. 1998;48(430):1245-1246. PubMed
4. Tylee A, Gastpar M, Line JP, et al; DEPRES Steering Committee. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. Int Clin Psychopharmacol. 1999;14(3):139-151. doi:10.1097/04850-1905030-01 PubMed
5. DeBattista C, Doghramji K, Menza MA, et al; Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary doubleblind, placebo-controlled study. J Clin Psychiatry. 2003;64(9):1057-1064. doi:10.408/JCP.v64n091 PubMed
6. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary. Vol 57. London, UK: BMJ Group and RPS Publishing; 2009.
7. Keitner GI, Solomon DA, Ryan CE, et al. Prodromal and residual symptoms in bipolar I disorder. Compr Psychiatry. 1996;37(5):362-367. doi:10.1016/S010-40X(96)9018-8 PubMed
8. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. doi:10.176/api.ajp.163.1.1905 PubMed
9. Fernandes PP, Petty F. Modafinil for remitted bipolar depression with hypersomnia. Ann Pharmacother. 2003;37(12):1807-1809. doi:10.1345/aph.1D26 PubMed
10. Kaplan KA, Gruber J, Eidelman P, et al. Hypersomnia in inter-episode bipolar disorder: does it have prognostic significance? J Affect Disord. 2011;132(3): 438-444. doi:10.1016/j.jad.201.03.013 PubMed
11. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50(2-3):97-108. doi:10.1016/S0165-0327(98) 0138-4 PubMed
12. Judd LL, Schettler PJ, Akiskal HS, et al. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/ recurrence. Arch Gen Psychiatry. 2008;65(4):386-394. doi:10.101/archpsyc.65.4. 386 PubMed
13. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164(8):1242-1249. doi:10.176/api.ajp.207.06060981 PubMed
14. Dell'Osso B, Ketter TA. Use of adjunctive stimulants in adult bipolar depression. Int J Neuropsychopharmacol. 2013;16(1): 55-68. PubMed
15. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33(7):1477-1502. doi:10.1038/sj.np.1301534 PubMed
16. Ishizuka T, Murotani T, Yamatodani A. Action of modafinil through histaminergic and orexinergic neurons. Vitam Horm. 2012;89:259-278. doi:10.1016/B978-0-12-394623-2.014-7 PubMed
17. Scoriels L, Barnett JH, Soma PK, et al. Effects of modafinil on cognitive functions in first episode psychosis. Psychopharmacology (Berl). 2012;220(2): 249-258. doi:10.107/s0213-01-2472-4 PubMed
18. Mler U, Rowe JB, Rittman T, et al. Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology. 2013;64:490-495. doi:10.1016/j.neuropharm.2012.07.09 PubMed
19. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry. 2000;61(5):378-381. doi:10.408/JCP.v61n0510 PubMed
20. Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev. 2008;16(2):CD006722. PubMed
21. Abolfazli R, Hosseini M, Ghanizadeh A, et al. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Depress Anxiety. 2011;28(4):297-302. doi:10.102/da.20801 PubMed
22. Dunlop BW, Crits-Christoph P, Evans DL, et al. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebocontrolled study. J Clin Psychopharmacol. 2007;27(6):614-619. doi:10.1097/jcp.0b013e31815abefb PubMed
23. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005;66(1): 85-93. doi:10.408/JCP.v6n012 PubMed
24. Calabrese JR, Ketter TA, Youakim JM, et al. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010;71(10):1363-1370. doi:10.408/JCP.09m0590gry PubMed
25. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002;36(4):578-584. doi:10.1345/aph.1A254 PubMed
26. Insel TR, Cuthbert BN, Garvey MA, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):748-751. doi:10.176/api.ajp.2010.09091379 PubMed
27. Morris SE, Cuthbert BN. Research Domain Criteria: cognitive systems, neural circuits, and dimensions of behavior. Dialogues Clin Neurosci. 2012; 14(1):29-37. PubMed
28. Konuk N, Atasoy N, Atik L, et al. Open-label study of adjunct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors. Adv Ther. 2006;23(4): 646-654. doi:10.107/BF0285053 PubMed
29. Thase ME, Fava M, DeBattista C, et al. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr. 2006;11(2): 93-102. PubMed
30. Fava M, Thase ME, DeBattista C, et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry. 2007;19(3):153-159. doi:10.1080/10401230701464858 PubMed
31. Masand PS, Anand VS, Tanquary JF. Psychostimulant augmentation of second generation antidepressants: a case series. Depress Anxiety. 1998;7(2): 89-91. doi:10.102/(SICI)1520-6394(198)7:2<89:AID-DA8>3.0.CO;2-0 PubMed
32. Gwirtsman HE, Szuba MP, Toren L, et al. The antidepressant response to tricyclics in major depressives is accelerated with adjunctive use of methylphenidate. Psychopharmacol Bull. 1994;30(2):157-164. PubMed
33. Abbasowa L, Kessing LV, Vinberg M. Psychostimulants in moderate to severe affective disorder: a systematic review of randomized controlled trials [published online ahead of print January 7, 2013]. Nord J Psychiatry. doi:10.3109/0803948.2012.752035 PubMed
34. Ravindran AV, Kennedy SH, O'Donovan MC, et al. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebocontrolled trial. J Clin Psychiatry. 2008;69(1):87-94. doi:10.408/JCP.v69n012 PubMed
35. Beddington J, Cooper CL, Field J, et al. The mental wealth of nations. Nature. 2008;455(7216):1057-1060. doi:10.1038/451057a PubMed
36. DeBattista C, Lembke A, Solvason HB, et al. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol. 2004;24(1):87-90. doi:10.1097/01.jcp.0104910.75206.b9 PubMed
37. Roiser JP, Elliott R, Sahakian BJ. Cognitive mechanisms of treatment in depression. Neuropsychopharmacology. 2012;37(1):117-136. doi:10.1038/np.201.183 PubMed
38. Walsh ND, Williams SCR, Brammer MJ, et al. A longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapy. Biol Psychiatry. 2007;62(11):1236-1243 doi:10.1016/j.biopsych.206.12.02 PubMed
39. Fu CHY, Mourao-Miranda J, Costafreda SG, et al. Pattern classification of sad facial processing: toward the development of neurobiological markers in depression. Biol Psychiatry. 2008;63(7):656-662. doi:10.1016/j.biopsych.207.08. 020 PubMed
40. Marquand AF, Mour-Miranda J, Brammer MJ, et al. Neuroanatomy of verbal working memory as a diagnostic biomarker for depression. Neuroreport. 2008;19(15):1507-1511.